Alfimeprase, a plasminogen-independent thrombolytic

IDrugs

Volumn 10, Issue 5, 2007, Pages 329-335

  Shah, Amit R ^a   Scher, Larry ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALFIMEPRASE; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CRL 42796; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBROLASE; HEPARIN; MN 447; PLACEBO; PLASMINOGEN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE; ZINC; FIBRINOLYTIC AGENT; METALLOPROTEINASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTERY OCCLUSION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CAROTID ARTERY THROMBOSIS; CATHETER OCCLUSION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMATOMA; HUMAN; HYPERTENSION; HYPOTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; THROMBUS; ANIMAL; ARTICLE; DRUG DESIGN; DRUG SCREENING; FIBRINOLYTIC THERAPY; PATENT; PERIPHERAL VASCULAR DISEASE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; UNITED STATES;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; HUMANS; METALLOENDOPEPTIDASES; PATENTS; PERIPHERAL VASCULAR DISEASES; PLASMINOGEN; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 34247594281     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 50208 Thrombolysis, anticoagulation, and re-occlusion. Rapaport E AM J CARDIOL 1991 68 16 17E-22E
2. 50236 Use of thrombolytic drugs in non-coronary disorders. Verstraete-M DRUGS 1989 38 5 801-821
3. 122531 The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Yamashita T, Yamamoto J, Sasaki Y, Matsuoka A THROMB RES 1993 69 1 93-100
4. 200400 Thrombolytic agents in development. Verstraete M, Lijnen HR, Collen D DRUGS 1995 50 1 29-42
5. 224886 Reteplase launched in Germany. SCRIP WORLD PHARMACEUTICAL NEWS 1996 2178 22
6. 239829 Reteplase and alteplase interchangable? SCRIP WORLD PHARMACEUTICAL NEWS 1997 2216 20
7. 288265 Integrilin available week of June 1st. COR Therapeutics Inc PRESS RELEASE 1998 May 27
8. 334891 New study shows RETAVASE provides superior benefits in patients with blood clots in the lung. Centocor Inc PRESS RELEASE 1999 August 02
9. 372891 Argatroban approved in US. SmithKline Beecham plc, Texas Biotechnology Corp PRESS RELEASE 2000 July 03
10. 402364 Integrilin and TNKase combination a rapid clot-buster. COR Therapeutics Inc PRESS RELEASE 2001 March 19
11. 435279 Amgen and Hyseq collaborate on novel acting thrombolytic. Hyseq Pharmaceuticals PRESS RELEASE 2002 January 10
12. 467796 Hyseq Pharmaceuticals Announces Third Quarter 2002 Financial Results Hyseq Inc PRESS RELEASE 2002 October 24
13. 477153 MPC launches antithrombin Novastan in China. PHARMA JAPAN 2003 1828 16
14. 480803 Nuvelo Inc - presentation to the BIO CEO & Investor conference Nuvelo Inc COMPANY PRESENTATION 2003 February 28
15. 492650 Disulfide structure of alfimeprase: A recombinant analog of fibrolase. Jones G, Ronk M, Mori F, Zhang Z PROTEIN SCI 2001 10 6 1264-1267
16. 500555 Drug datasheet: TNKase (tenecteplase) single-bolus. Genentech Inc DRUG DATASHEET WEBSITE 2000 June 01
17. 542399 Nuvelo's alfimeprase shows promise in phase II arterial occlusion trial. Nuvelo Inc PRESS RELEASE 2004 June 05
18. 568005 Nuvelo to acquire alfimeprase rights from Amgen Nuvelo Inc PRESS RELEASE 2004 November 01
19. 572677 Safety and efficacy of alfimeprase for restoring function in occluded central venous catheters: Interim results of a phase 2, multicenter, randomized, double-blind study (NuCath). Deitcher SR, Moll S, Homesley HD, Bertoli L, Kenyon P, Swischuk P, Pena L BLOOD 2004 104 11 Abs 1768
20. 576128 Alpha-fibrinogenases. Swenson S, Toombs CF, Pena L, Johansson J, Markland FS Jr CURR DRUG TARGETS-CARDIOVASC HAEMATOL DISORD 2004 4 4 417-435
21. 633403 Nuvelo's alfimeprase gets Orphan Drug designation Nuvelo Inc PRESS RELEASE 2005 November 09
22. 643629 Nuvelo and Bayer HealthCare enter comprehensive collaboration agreement to maximize global development and commercialization of alfimeprase. Nuvelo Inc PRESS RELEASE 2006 January 05
23. 644631 A phase I trial of alfimeprase for peripheral arterial thrombolysis. Ouriel K, Cynamon J, Weaver FA, Dardik H, Akers D, Blebea J, Gruneiro L, Toombs CF, Wang-Clow F, Mohler M, Pena L et al J VASC INTERV RADIOL 2005 16 8 1075-1083
24. 646258 Nuvelo's alfimeprase gets US Fast Track status for occlusion PRESS RELEASE 2006 January 23
25. 677346 Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. Moll S, Kenyon P, Bertoli L, DeMaio J, Homesley H, Deitcher SR J CLIN ONCOL 2006 24 19 3056-3060
26. 732832 Effect of thrombolysis on myocardial injury: Recombinant tissue plasminogen activator vs alfimeprase. Hong TT, Huang J, Lucchesi BR AM J PHYSIOL - HEART CIRCULAT PHYSIOL 2006 290 3 H959-H967
27. 732836 Non-clinical and clinical characterization of a novel acting thrombolytic: Alfimeprase. Deitcher SR, Toombs CF PATHOPHYSIOL HAEMOST THOMB 2005 34 4-5 215-220
28. 732838 Alfimeprase: Pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Toombs CF HAEMOSTASIS 2001 31 3-6 141-147
29. 736960 MediciNova licenses Meiji's antithrombotics. MediciNova Inc PRESS RELEASE 2006 November 01
30. 737769 Alfimeprase, a novel direct-acting fibrinolytic agent in acute peripheral arterial occlusion: Report of a phase 2, multi-center, open-label, dose-defining study (NAPA-1). NAPA Investigators CIRCULATION 2006 114 18 Suppl Abs 2777/C240
31. 749969 Nuvelo and Bayer's alfimeprase fails in phase III PAO trial. Nuvelo Inc PRESS RELEASE 2006 December 11
32. 766068 Thrombolytic therapy of acute myocardial infarction. de Bono DP BAILLIERES CLIN HAEMATOL 1995 8 2 403-412
33. 766077 Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (Agkistrodon contortrix contortrix). Guan AL, Retzios AD, Henderson GN, Markland FS ARCH BIOCHEM BIOPHYS 1991 289 2 197-207
34. 766092 Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom. Ahmed NK, Tennant KD, Markland FS, Lacz JP HAEMOSTASIS 1990 20 3 147-154
35. 768555 Development overview: Alfimeprase. Nuvelo Inc COMPANY WORLD WIDE WEB SITE 2007 February 26
36. 778236 The importance of increasing public and physician awareness of peripheral arterial disease. Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT J VASC INTERV RADIOL 2002 13 1 7-11
37. 778240 Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S et al CIRCULATION 2007 113 6 85e-151e
38. 780646 Thrombolytic therapy for acute arterial occlusion. Ouriel K CURR OPIN GEN SURG 1994 257-264
39. 780649 Thrombolytic therapy for acute arterial occlusion. Sicard GA, Schier JJ, Totty WG, Gilula LA, Walker WB, Etheredge EE, Anderson CB J VASC SURG 1985 2 1 65-78